Status:
UNKNOWN
Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC
Lead Sponsor:
Guangzhou Institute of Respiratory Disease
Collaborating Sponsors:
GeneCast Biotechnology Co., Ltd.
Conditions:
NSCLC
Eligibility:
All Genders
18-70 years
Brief Summary
Immunotherapy for PD-L1 positive patients is still ineffective in some patients，which may be related to the complex immune microenvironment.In view of this bottleneck, further refinement of immunotypi...
Detailed Description
There are still some patients with PD-L1 positive who are ineffective in immunotherapy, which may be related to the complex immune microenvironment. In view of this bottleneck, further refinement of i...
Eligibility Criteria
Inclusion
- Non small cell lung cancer was diagnosed by cytology or histopathology;
- Patients to be treated with PD-1 / PD-L1 inhibitors;
- Who signed the informed consent for participating in the research plan
Exclusion
- History of other malignancies
- Cancer meningitis in subjects
- Incomplete clinical follow-up data
- Failure to sign informed consent to participate in the research program
Key Trial Info
Start Date :
April 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04405661
Start Date
April 28 2020
End Date
May 30 2022
Last Update
May 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510120